Key result
AngA-sEV-Lip@Gla nanoparticles alleviate doxorubicin-induced cardiotoxicity in mice by restoring autophagic flux.
Why the study?
Impaired autophagic flux is a core mechanism of doxorubicin-induced cardiotoxicity, and while glabridin has cardioprotective effects, its poor water solubility and limited myocardial-targeting capability hinder clinical translation.
Does AngA-sEV-Lip@Gla restore autophagic flux and protect against doxorubicin-induced cardiotoxicity in preclinical cardiomyocyte and mouse models?
Does AngA-sEV-Lip@Gla restore autophagic flux and protect against doxorubicin-induced cardiotoxicity in preclinical cardiomyocyte and mouse models?
Provides preclinical evidence that targeted delivery of glabridin via AngA-modified sEV-liposome hybrid nanoparticles protects against doxorubicin-induced cardiotoxicity by restoring autophagic flux through ATG5 modulation.
Answers are grounded in this paper and cite their sources.
Nanocarrier-enhanced glabridin may aid DIC autophagy restoration; leaves open clinical translation and requires prospective trials before practice change.
Doxorubicin-induced cardiotoxicity (DIC) limits its clinical application and poses a significant risk to cancer patients, with impaired autophagic flux considered a core mechanism underlying DIC. Although glabridin (Gla) exhibits prominent cardioprotective effects, its poor water solubility and limited myocardial-targeting capability hinder its clinical translation. Therefore, improving the myocardial-targeting properties of Gla and restoring autophagy are critical for the treatment of DIC. In this study, we prepared angiotensin A (AngA)‑modified bone marrow mesenchymal stem cell (BMSC)-derived small extracellular vesicle (sEV)‑liposome hybrid nanoparticles and loaded them with Gla (AngA-sEV-Lip@Gla). We evaluated their myocardial-targeting capability, therapeutic efficacy against DIC, and ability to restore autophagic flux. Click chemistry-activity-based protein profiling (CC-ABPP) and site-directed mutagenesis were employed to identify the molecular target and signaling pathway of Gla. Our results demonstrated the successful establishment of AngA-sEV-Lip@Gla. In vitro and in vivo experiments showed that AngA-sEV-Lip@Gla efficiently targeted myocardial tissue and achieved favorable lysosomal escape. AngA-sEV-Lip@Gla also markedly alleviated DOX-induced cardiomyocyte injury, oxidative stress, and mitochondrial dysfunction, while ameliorating cardiac dysfunction, myocardial pathological damage, and fibrosis in DIC model mice. Mechanistic studies indicated that Gla might act at the MET173 site of ATG5 to upregulate the expression of the ATG5–ATG12–ATG16L1 complex, thereby restoring blocked autophagic flux in cardiomyocytes and exerting cardioprotective effects. In summary, AngA-sEV-Lip@Gla targets the MET173 site of ATG5 to modulate the ATG5–ATG12–ATG16L1 complex and restore autophagic flux, thereby effectively protecting against DIC. Our study provides novel mechanistic insights and experimental support for the clinical prophylaxis and treatment of DIC.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2026) studied Doxorubicin-induced cardiotoxicity (DIC). AngA-modified bone marrow mesenchymal stem cell-derived small extracellular vesicle-liposome hybrid nanoparticles loaded with Glabridin (AngA-sEV-Lip@Gla) was evaluated on Myocardial-targeting capability, restoration of autophagic flux, and therapeutic efficacy against doxorubicin-induced cardiotoxicity (cardiac dysfunction, myocardial pathological damage, and fibrosis). AngA-sEV-Lip@Gla nanoparticles targeted the MET173 site of ATG5 to restore autophagic flux and alleviate doxorubicin-induced cardiotoxicity in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: